Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2

Código QR

Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new pharmacological alternative for the treatment of diabetes. Aim: To report our experience with the use of this type of drugs in type 2 diabetics treated in an outpatient clinic. Material and Methods: We selected 77 type 2 dia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Contreras,Álvaro, Grassi,Bruno, Alfaro,Daniela, González,Felipe, Ortega,Valeska
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2019
Materias:	Albuminuria Diabetes Mellitus Type 2 Hypoglycemic Agents Sodium-Glucose Transporter 2 Inhibitors
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000901093
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Diabetes Mellitus tipo 2 con tendencia a la cetosis: Caso clínico
por: Concha L,Luciana, et al.
Publicado: (2015)

Cetoacidosis diabética euglicémica asociada a inhibidor de cotransportador de sodio glucosa Tipo 2 en paciente con diabetes Mellitus Tipo 1
por: Novik A,Victoria, et al.
Publicado: (2017)

SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
por: Vladimir V Salukhov, et al.
Publicado: (2021)

Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
por: Godoy J,Gonzalo, et al.
Publicado: (2015)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Fan Yang, et al.
Publicado: (2020)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019)

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
por: Men P, et al.
Publicado: (2020)

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
por: David Bobrowski, et al.
Publicado: (2021)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora BM, et al.
Publicado: (2020)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Santos Cavaiola T, et al.
Publicado: (2018)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
por: Ito H, et al.
Publicado: (2019)

Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
por: Ji-Yeon Lee, et al.
Publicado: (2021)

Eficacia de los hipoglicemiantes orales en el control metabólico de pacientes con diabetes mellitus gestacional
por: Valdés R,Enrique, et al.
Publicado: (2008)

Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes
por: Song L, et al.
Publicado: (2021)

Second line therapy in type 2 diabetes: legacy effect activation
por: Ekaterina A. Shestakova
Publicado: (2017)

The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
por: Hirai K, et al.
Publicado: (2020)

Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
por: K. Tobe, et al.
Publicado: (2021)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
por: A. M. Mkrtumyan, et al.
Publicado: (2021)

Comparative pharmacoepidemiological study of antihyperglycemic drugs utilization by patients with type 2 diabetes mellitus in Moscow
por: Marina F. Kalashnikova, et al.
Publicado: (2016)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies MJ, et al.
Publicado: (2017)

Efecto de un inhibidor tirosina kinasa (imatinib) en pacientes con tumores estromales gastrointestinales metastásicos: Experiencia preliminar
por: Garrido S,Marcelo, et al.
Publicado: (2007)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Jadwiga Nessler
Publicado: (2021)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou I, et al.
Publicado: (2019)

Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up
por: Celestino Sardu, et al.
Publicado: (2021)

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
por: Gagik Radikovich Galstyan
Publicado: (2013)

Type 2 diabetes mellitus in elderly patients treated with endocrinologists in clinical practice
por: Elena V. Biryukova
Publicado: (2019)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
por: Marina V. Shestakova, et al.
Publicado: (2017)

Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010)

Drug-drug Interactions between Hypoglycemic and Non-hypoglycemic Medication in Diabetic Patients with Comorbidities in a Tertiary Care Center: A Descriptive Cross-sectional Study
por: Lujaw Ratna Tuladhar, et al.
Publicado: (2021)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen T, et al.
Publicado: (2020)

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
por: Angelo Avogaro
Publicado: (2018)

Influencia de la enfermedad periodontal en el control metabólico de pacientes con diabetes mellitus tipo 2: Revisión de la literatura
por: STEFFENS,JOÃO PAULO, et al.
Publicado: (2010)

Microalbuminuria y excreción urinaria de albúmina en la práctica clínica
por: Tagle,Rodrigo, et al.
Publicado: (2012)

Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus
por: Alexander Sergeevich Ametov, et al.
Publicado: (2013)

Glicemia de ayuno versus prueba de tolerancia oral a la glucosa en la detección de intolerancia a la glucosa en niños y adolescentes obesos
por: Gallardo T,Vivian, et al.
Publicado: (2006)

Pharmacogenetics of hypoglycemic agents
por: Irina Vladimirovna Kononenko, et al.
Publicado: (2015)

Ejercicio intermitente y consejería nutricional mejoran control glicémico y calidad de vida en pacientes con diabetes mellitus tipo 2
por: Mangiamarchi,Pedro, et al.
Publicado: (2017)

Cross-sectional and longitudinal assessments of risk factors associated with hypertension and moderately increased albuminuria comorbidity in patients with type 2 diabetes: a 9-year open cohort study
por: Hadi Alijanvand M, et al.
Publicado: (2019)